Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days
Gachon University Of Industry-Academic Cooperation Foundation has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These 2 actions are assigned to 2 distinct examiners across 2 distinct art units. This indicates that the university's current pending matters are technically diverse within the biotechnology sector.
KWON, JOHN SEUNGJAI is the busiest examiner with 1 pending office action. Since each pending action is with a different examiner in a different art unit, there is no centralized point of contact for the portfolio. Practitioners should prepare for two independent prosecution tracks, each tailored to the specific examiner and art unit involved in the review process.
With 2 distinct art units involved, the applications are subject to different sets of examination guidelines and technical standards. The lack of overlap between the 2 distinct examiners means that prosecution progress in one matter may not necessarily predict the results of the other. Success requires a tailored approach for each of the 2 pending office actions to navigate the unique preferences of the assigned officials.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KWON, JOHN SEUNGJAI | 1 | 44.9% | +20.2% |
| CONNORS, ALEXANDRA F | 1 | 23.7% | +45.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18979865 | NIR-responsive stem cell-derived inflammation attenuating complex and use thereof | KWON, JOHN SEUNGJAI | — |
| 17674233 | Method of enhancing mobility of stem cells to inflammatory lesion | CONNORS, ALEXANDRA F | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18979865 | NIR-responsive stem cell-derived inflammation attenuating complex and use thereof | KWON, JOHN SEUNGJAI | — |
| 17674233 | Method of enhancing mobility of stem cells to inflammatory lesion | CONNORS, ALEXANDRA F | — |
| Art Unit | Apps |
|---|---|
| 1615 | 1 |
| 1634 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18979865 | NIR-responsive stem cell-derived inflammation attenuating complex and use thereof | KWON, JOHN SEUNGJAI | 1615 | §103§112 | Non-Final OA | — | Pending | Dec 13, 2024 |
| 17674233 | Method of enhancing mobility of stem cells to inflammatory lesion | CONNORS, ALEXANDRA F | 1634 | §103 | Final Rejection | — | Pending | Feb 17, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialGachon University Of Industry-Academic Cooperation Foundation has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
John Seungjai Kwon has the most, with 1 of Gachon University Of Industry-Academic Cooperation Foundation's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
